Company Northwest Biotherapeutics, Inc. Other OTC
Equities
NWBO
US66737P6007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 16/05/07 |
Alton L. Boynton
FOU | Founder | 79 | 17/03/96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 31/12/99 |
David Innes
IRC | Investor Relations Contact | - | 25/02/19 |
General Counsel | 78 | 31/05/11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 17/03/96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 16/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 31/03/12 |
Director/Board Member | 74 | 26/01/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,200,000 | 0 | 0 | 90.82 % |
Stock B | 1 | 1,208,177,416 | 1,097,287,981 ( 90.82 %) | 0 |
Company contact information
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSector
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |